Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 8/20 | 0.33 |
| ▸ | MAOA | P21397 | 6/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA4 | P22748 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677229 | 0.89 | GSTP1 (0.42) | GSTP1MAOBMAOAKAT6ATSHR | |
| SCHEMBL4678875 | 0.79 | NQO1 (0.34) | KAT6A | |
| SCHEMBL4741234 | 0.78 | GSTP1 (0.36) | GSTP1LMNAMAOBMAOAKAT6A | |
| SCHEMBL4678195 | 0.76 | HTT (0.36) | HTT | |
| SCHEMBL4677635 | 0.75 | KDR (0.37) | LMNAHTTTSHR | |
| SCHEMBL4681126 | 0.75 | HTR2C (0.36) | LMNAMAOBKAT6AHPGDTSHR | |
| SCHEMBL4677644 | 0.75 | HTT (0.44) | HTTTSHR | |
| SCHEMBL15544932 | 0.75 | TAAR1 (0.52) | LMNAMAOBMAOAHTT | |
| SCHEMBL4682285 | 0.74 | PARP10 (0.41) | KAT6A | |
| SCHEMBL4682530 | 0.74 | SLC6A4 (0.39) | LMNAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | GSTP1 1061/4885LMNA 4209/4885MAOB 2221/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | GSTP1 1061/4885LMNA 4209/4885MAOB 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.